Search results
Showing 2596 to 2610 of 7687 results
Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.
View recommendations for MTG56Show all sections
Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.
We are listening to your views on this Interventional procedures guidance. Comments close 12 December 2024.
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: 26 February 2025
In development [GID-TA11405] Expected publication date: TBC
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease
Evidence-based recommendations on Kinesia 360 and KinesiaU (Great Lakes NeuroTechnologies), PDMonitor (PD Neurotechnology), Personal KinetiGraph (Global Kinetics) and STAT-ON (Sense4care) for remote monitoring of Parkinson’s disease
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (DG6)
Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery
Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making